Drug Profile

Anti-BCMA chimeric antigen receptor NK-cell therapy - Takeda/The University of Texas MD Anderson Cancer Center

Alternative Names: Anti-BCMA CAR NK-cell therapy - Takeda/The University of Texas MD Anderson Cancer Center

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Texas M. D. Anderson Cancer Center
Developer Takeda; University of Texas M. D. Anderson Cancer Center
Class Gene therapies; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Dec 2023 No recent reports of development identified for research development in Cancer in USA (Parenteral)
06 Nov 2019 BCMA CAR NK-cell therapy licensed to Takeda
06 Nov 2019 Early research in Cancer in USA (Parenteral) before November 20198

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com